Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, Texas, USA.
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):299-306. doi: 10.1089/jamp.2024.27498.bp.
Inhalable particulate drug carriers-nano- and micro-particles, liposomes, and micelles-should be designed to promote drug deposition in the lung and engineered to exhibit the desired drug release property. To deposit at the desired site of action, inhaled particles must evade various lines of lung defense, including mucociliary clearance, entrapment by mucus layer, and phagocytosis by alveolar macrophages. Various physiological, mechanical, and chemical barriers of the respiratory system reduce particle residence time in the lungs, prevent particle deposition in the deep lung, remove drug-filled particles from the lung, and thus diminish the therapeutic efficacy of inhaled drugs. To develop inhalable drug carriers with efficient deposition properties and optimal retention in the lungs, particle engineers should have a thorough understanding of the barriers that particles confront and appreciate the lung defenses that remove the particles from the respiratory system. Thus, this section summarizes the mechanical, chemical, and immunological barriers of the lungs that inhaled particles must overcome and discusses the influence of these barriers on the fate of inhaled particles.
可吸入颗粒药物载体 - 纳米和微颗粒、脂质体和胶束 - 应设计为促进药物在肺部的沉积,并设计为表现出所需的药物释放特性。为了在预期的作用部位沉积,吸入的颗粒必须逃避各种肺部防御机制,包括黏液纤毛清除、被黏液层捕获和肺泡巨噬细胞吞噬。呼吸系统的各种生理、机械和化学屏障会减少颗粒在肺部的停留时间,防止颗粒在肺部深部沉积,将充满药物的颗粒从肺部清除,从而降低吸入药物的治疗效果。为了开发具有高效沉积性能和在肺部最佳保留的可吸入药物载体,颗粒工程师应该充分了解颗粒所面临的障碍,并了解从呼吸系统中清除颗粒的肺部防御机制。因此,本节总结了吸入颗粒必须克服的肺部机械、化学和免疫学屏障,并讨论了这些屏障对吸入颗粒命运的影响。